Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Addition of reserpine to antipsychotic medication in refractory chronic schizophrenic outpatients.

Bacher NM, Lewis HA.

Am J Psychiatry. 1978 Apr;135(4):488-9. No abstract available.

PMID:
25024
2.

Long-term reserpine use in selected refractory outpatients.

Bacher N, Lewis HA.

Am J Psychiatry. 1985 Mar;142(3):386-7. No abstract available.

PMID:
2857536
3.

Piperacetazine vs. thioridazine for the control of schizophrenia in outpatients.

Rada RT, Donlon PT.

Psychosomatics. 1972 Nov-Dec;13(6):373-6. No abstract available.

PMID:
4153002
4.

Addition of reserpine to ongoing neuroleptic exposure in chronic schizophrenia.

Perenyi A, Goswani U, Bela A, Freoska E, Arato M, Hegedus I.

Schizophr Res. 1988 Jul-Aug;1(4):307-8. No abstract available.

PMID:
2908704
5.
6.

Possible enhancing effects of diazepam with reserpine in a chronic schizophrenic patient with tardive dyskinesia.

Bacher NM, Field PB, Elkashef A.

J Clin Psychopharmacol. 1989 Aug;9(4):312. No abstract available.

PMID:
2570090
7.

High-dose antipsychotic medication.

Bennie EH.

Br J Psychiatry. 1994 Oct;165(4):553. No abstract available.

PMID:
7528625
8.

Neuroleptics and reserpine in refractory psychoses.

Berlant JL.

J Clin Psychopharmacol. 1986 Jun;6(3):180-4.

PMID:
2872238
9.
10.

Addition of lithium to neuroleptic treatment in chronic schizophrenia.

Lewis HA, Bacher NM, Field PB.

Am J Psychiatry. 1986 Feb;143(2):262. No abstract available.

PMID:
2868667
11.

[Pharmaco-epidemiological study on antipsychotic drug prescription in French Psychiatry: Patient characteristics, antipsychotic treatment, and care management for schizophrenia].

Brunot A, Lachaux B, Sontag H, Casadebaig F, Philippe A, Rouillon F, Cléry-Melin P, Hergueta T, Llorca PM, Moreaudefarges T, Guillon P, Lebrun T.

Encephale. 2002 Mar-Apr;28(2):129-38. French.

PMID:
11972139
12.

Attitudes toward antipsychotic medication, insight and psychopathology in outpatients with schizophrenia.

Vassileva IV, Milanova VK.

Folia Med (Plovdiv). 2012 Oct-Dec;54(4):62-8.

PMID:
23441471
13.

A comparative trial of pharmacologic strategies in schizophrenia.

Carpenter WT Jr, Heinrichs DW, Hanlon TE.

Am J Psychiatry. 1987 Nov;144(11):1466-70.

PMID:
2890307
14.

Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms.

Arango C, Kirkpatrick B, Buchanan RW.

J Nerv Ment Dis. 2000 Jan;188(1):50-3. No abstract available.

PMID:
10665462
15.

Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.

Faraone SV, Brown WA, Laughren TP.

J Clin Psychiatry. 1987 Apr;48(4):151-4.

PMID:
2881923
16.

Specific indications for different classes of phenothiazines.

Hollister LE, Overall JE, Kimbell I Jr, Pokorny A.

Arch Gen Psychiatry. 1974 Jan;30(1):94-9. No abstract available.

PMID:
4148660
17.

Akathisia: clinical phenomenology and relationship to tardive dyskinesia.

Kahn EM, Munetz MR, Davies MA, Schulz SC.

Compr Psychiatry. 1992 Jul-Aug;33(4):233-6.

PMID:
1353716
18.

[Hypotensive effects of fursemide, triamterene and reserpine combination in patients with essential hypertension on ambulatory care].

Saldanha RV, Veras RO, de Paula e Silva P, de Serro-Azul LG.

Rev Paul Med. 1971 Nov;78(4):137-40. Portuguese. No abstract available.

PMID:
5164638
19.

Monthly intermittent chemotherapy of chronic schizophrenic outpatients with pipothiazine palmitate.

Laurent JS, Carle R, Dumais B, Domingue D.

Can Psychiatr Assoc J. 1974 Dec;19(6):583-91. No abstract available.

PMID:
4155349
20.

Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study.

Novick D, Bousono M, Suarez D, Olivares JM, Montejo AL, Haro JM, Edgell ET, Ratcliffe M; SOHO Advisory Board.

Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):972-82.

PMID:
16023776

Supplemental Content

Support Center